UNSPSC 51373465: Guaifenesin/hydrocodone/pheniramine/phenylpropanolamine/pyrilamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373465 Guaifenesin/hydrocodone/pheniramine/phenylpropanolamine/pyrilamine is a Commodity code that nominally specifies a combination cough-and-cold pharmaceutical, but the recent state and local opportunities tagged to it diverge sharply from this definition. The solicitation record shows naloxone (an opioid-reversal medication), safe drug deactivation systems, and multi-source generic pharmaceuticals with over-the-counter products — none of which match the code's stated composition. State and local purchasing offices are using this code as a catch-all for pharmaceutical procurement rather than for the specific active-ingredient combination the code nominally describes. The actual scope of work under current solicitation activity spans emergency-response pharmaceuticals, harm-reduction supplies, and broad generic pharmaceutical supply agreements distributed through authorized wholesalers to multiple government facilities.

Issuing bodies include county health departments (Seminole County, Florida) and multistate cooperative purchasing alliances administering on behalf of state and local members (the Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, with participation from Oregon and other jurisdictions). Recent opportunities show activity in Florida and Minnesota, with MMCAP's cooperative model extending across multiple states. The Seminole County IFB (IFB60459723LAS), posted June 30, 2026, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (an apparent date-entry error in the source). The MMCAP RFP (S1070000015802), posted January 20, 2026, established multiple contracts for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with proposals due March 26, 2026 and contract effectiveness set for July 1, 2026. No specific set-aside designations appear in either solicitation. The code shows limited recent activity and a poor alignment between the nominal pharmaceutical composition and actual procurement scope.